Riekie Smit1,2,3,4,5,6,7, Elena Gubanova1,2,3,4,5,6,7, Joely Kaufman1,2,3,4,5,6,7, Marina Landau1,2,3,4,5,6,7, Beatriz Molina1,2,3,4,5,6,7, Bill Andriopoulos1,2,3,4,5,6,7, Pascal Maisonobe1,2,3,4,5,6,7, Inna Prygova1,2,3,4,5,6,7, Alessio Redaelli1,2,3,4,5,6,7. 1. Dr. Smit is with the Dr. Riekie Smit Aesthetic Medical Practice in Pretoria, South Africa. 2. Dr. Gubanova is with Vallex Med Clinic of Preventive Medicine, Moscow National University of Food Production in Moscow, Russian Federation. 3. Dr. Kaufman is with the University of Miami, Miller School of Medicine and Skin Associates of South Florida in Coral Gables, Florida, United States of America. 4. Dr. Landau is with Wolfson Medical Center in Holon, Israel. 5. Dr. Molina is with Medikas Medispa in Street, Somerset, United Kingdom. 6. Dr. Andriopoulos is with Galderma Aesthetics in Uppsala, Sweden. Mr. Maisonobe and Dr. Prygova are with Ipsen Pharma, Boulogne-Billancourt, France. 7. Dr. Redaelli is with the Visconti di Modrone Medical Center in Milan, Italy.
Abstract
BACKGROUND: AbobotulinumtoxinA (AboBoNT-A; Dysport®; Ipsen, Boulogne-Billancourt, France/Azzalure®; Galderma, Lausanne, Switzerland) is a botulinum neurotoxin type A approved for aesthetic use in the treatment of glabellar lines in adult patients under 65 years in Europe, the United States, and other countries. OBJECTIVE: We sought to analyze current literature on patient satisfaction with aboBoNT-A for upper facial aesthetic indications. METHODS: A systematic review of literature databases (PubMed/MEDLINE, Embase, the Cochrane Library, and Google Scholar) was performed to identify English-language publications reporting on patients with aesthetic indications (including glabellar lines and wrinkles) receiving aboBoNT-A, that assessed patient and/or physician satisfaction with treatment, with no restrictions on comparator studies. Structured data extraction was used to enable inter-study analysis. A post-hoc analysis was also performed to assess patient satisfaction by sex and age, using results from the noninterventional APPEAL study of patients' satisfaction with aboBoNT-A for treating glabellar lines. RESULTS: Overall, 22 original research papers were identified. Patient satisfaction rates for aboBoNT-A treatment were significantly higher versus placebo from two weeks to between three and five months postinjection. At two to three weeks postinjection, patient satisfaction rates were 52% and 99% across studies. In studies with later time points, patient satisfaction rates were 85 to 87 percent at 5 months and between 25 and 100 percent at 6 months post-injection. Physician satisfaction was also high (97%-100%, across three treatments). No notable differences in patient satisfaction by sex or age were observed in the APPEAL study. CONCLUSION: High rates of patient satisfaction have been achieved with aboBoNT-A treatment for upper facial aesthetic indications. Despite the current recommended interval of ≥12 weeks, satisfaction with the aesthetic results of aboBoNT-A therapy is still evident up to 6 months post-injection in some patients.
BACKGROUND: AbobotulinumtoxinA (AboBoNT-A; Dysport®; Ipsen, Boulogne-Billancourt, France/Azzalure®; Galderma, Lausanne, Switzerland) is a botulinum neurotoxin type A approved for aesthetic use in the treatment of glabellar lines in adult patients under 65 years in Europe, the United States, and other countries. OBJECTIVE: We sought to analyze current literature on patient satisfaction with aboBoNT-A for upper facial aesthetic indications. METHODS: A systematic review of literature databases (PubMed/MEDLINE, Embase, the Cochrane Library, and Google Scholar) was performed to identify English-language publications reporting on patients with aesthetic indications (including glabellar lines and wrinkles) receiving aboBoNT-A, that assessed patient and/or physician satisfaction with treatment, with no restrictions on comparator studies. Structured data extraction was used to enable inter-study analysis. A post-hoc analysis was also performed to assess patient satisfaction by sex and age, using results from the noninterventional APPEAL study of patients' satisfaction with aboBoNT-A for treating glabellar lines. RESULTS: Overall, 22 original research papers were identified. Patient satisfaction rates for aboBoNT-A treatment were significantly higher versus placebo from two weeks to between three and five months postinjection. At two to three weeks postinjection, patient satisfaction rates were 52% and 99% across studies. In studies with later time points, patient satisfaction rates were 85 to 87 percent at 5 months and between 25 and 100 percent at 6 months post-injection. Physician satisfaction was also high (97%-100%, across three treatments). No notable differences in patient satisfaction by sex or age were observed in the APPEAL study. CONCLUSION: High rates of patient satisfaction have been achieved with aboBoNT-A treatment for upper facial aesthetic indications. Despite the current recommended interval of ≥12 weeks, satisfaction with the aesthetic results of aboBoNT-A therapy is still evident up to 6 months post-injection in some patients.
Authors: Mark Nestor; Joel L Cohen; Marina Landau; Said Hilton; Andreas Nikolis; Syed Haq; Maurizio Viel; Bill Andriopoulos; Inna Prygova; Keith Foster; Alessio Redaelli; Philippe Picaut Journal: J Clin Aesthet Dermatol Date: 2020-12-01
Authors: B Molina; Y Grangier; B Mole; N Ribe; L Martín Diaz; W Prager; F Paliargues; N Kerrouche Journal: J Eur Acad Dermatol Venereol Date: 2014-12-12 Impact factor: 6.166
Authors: Hema Sundaram; Po-Han Huang; Nai-Jen Hsu; Chang Hun Huh; Woffles T L Wu; Yan Wu; Daniel Cassuto; Martina J Kerscher; Kyle Koo-Il Seo Journal: Plast Reconstr Surg Glob Open Date: 2016-12-07
Authors: Steven Dayan; John Joseph; Amir Moradi; Z Paul Lorenc; Kyle Coleman; Glynis Ablon; Joely Kaufman-Janette; Sue Ellen Cox; Andrew Campbell; Girish Munavalli; Inna Prygova Journal: J Cosmet Dermatol Date: 2022-04-12 Impact factor: 2.189